Guangdong Dongyang Guangyao Pharmaceutical

HEC Pharma is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of drugs across anti-viral, endocrine, and cardiovascular therapeutic areas. The company holds a dominant market position in China's anti-influenza sector with its flagship product Kewei (oseltamivir phosphate), which accounts for a significant portion of its revenue. Beyond its core anti-viral portfolio, HEC Pharma has established a robust pipeline of innovative small molecules and biologics targeting chronic diseases such as Hepatitis C and Type 2 diabetes. As a core subsidiary of the HEC Group, the company operates large-scale manufacturing facilities and maintains an extensive domestic distribution network. HEC Pharma continues to transition from a generic-focused manufacturer to an innovation-driven biotech through its R&D arm, Sunshine Lake Pharma.